Cargando…

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells

BACKGROUND: Neuroblastoma is the most common pediatric extra-cranial nervous system tumor, originating from neural crest elements and giving rise to tumors in the adrenal medulla and sympathetic chain ganglia. Amplification of MYCN confers increased malignancy and poorer prognosis in high-risk neuro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanna, Reine, Abdallah, Jad, Abou-Antoun, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868539/ https://www.ncbi.nlm.nih.gov/pubmed/33569349 http://dx.doi.org/10.3389/fonc.2020.624560

Ejemplares similares

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration
por: Zaatiti, Hayat, et al.
Publicado: (2018)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma
por: Bellamy, Jacob, et al.
Publicado: (2020)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
por: Weber, Helga, et al.
Publicado: (2017)

Repercussion of Mitochondria Deformity Induced by Anti-Hsp90 Drug 17AAG in Human Tumor Cells
por: Vishal, Chaturvedi, et al.
Publicado: (2011)

Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?()
por: Mehta, Adi, et al.
Publicado: (2013)

MYCN-amplified neuroblastoma cell-derived exosomal miR-17-5p promotes proliferation and migration of non-MYCN amplified cells
por: Chen, Weiming, et al.
Publicado: (2021)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer
por: Zajac, Magdalena, et al.
Publicado: (2010)

HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70
por: Liu, Min, et al.
Publicado: (2020)

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
por: Yu, Yajie, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin)
por: Patwardhan, Chaitanya A., et al.
Publicado: (2023)

17AAG Treatment Accelerates Doxorubicin Induced Cellular Senescence: Hsp90 Interferes with Enforced Senescence of Tumor Cells
por: Sarangi, Upasana, et al.
Publicado: (2012)

The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes
por: Miyoshi, Sadanori, et al.
Publicado: (2012)

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
por: Powers, Marissa V, et al.
Publicado: (2013)

Topically applied Hsp90 inhibitor 17AAG inhibits ultraviolet radiation-induced cutaneous squamous cell carcinomas
por: Singh, Anupama, et al.
Publicado: (2014)

HSP90 Inhibitor 17-AAG Attenuates Nucleus Pulposus Inflammation and Catabolism Induced by M1-Polarized Macrophages
por: Zhang, Shuo, et al.
Publicado: (2022)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
por: Vaseva, A V, et al.
Publicado: (2011)

NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG
por: Kasai, Shuya, et al.
Publicado: (2016)

ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma
por: Huynh, Tony, et al.
Publicado: (2012)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin
por: Gherardi, Samuele, et al.
Publicado: (2013)

A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma
por: Krstic, Aleksandar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q000mjb7fcum30190uuc0428kt